Locations:
Multidisciplinary team tackles the management of 84 uncommon cancers and blood disorders
Treatment may be a lifesaving option for patients with relapsed or refractory disease
Study reports on 11-year experience in AML
Preliminary trial reports positive patient response
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Results of two studies presented at the 2020 ASH Annual Meeting
Trial results point the way to further investigation
TETi76 eliminates TET2-mutant and TET-deficient cancer cells
Dose-finding trial adds to evidence of efficacy
Four genomic clusters identified
A major advance in prognosis for myelodysplastic syndromes that may improve outcomes
Advertisement
Advertisement
Search